57 -12 (62) 2023 — Amonov M.K. — APPLICATION OF A HYPOGLYCEMIC DRUG IN HEART FAILURE WITH PRESERVED EFCILIAR FRACTION WITH AND WITHOUT AFIBLIAR ARRHYTHMIA

APPLICATION OF A HYPOGLYCEMIC DRUG IN HEART FAILURE WITH PRESERVED EFCILIAR FRACTION WITH AND WITHOUT AFIBLIAR ARRHYTHMIA

Amonov M.K.  Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Atrial fibrillation/flutter (AF) is common in heart failure (HF) with preserved left ventricular ejection fraction (LVEF) and is associated with worse outcomes. The hypoglycemic agent Empagliflozin reduces cardiovascular mortality or hospitalization for HF and slows the decline in estimated glomerular filtration rate (eGFR) in patients with HF and LVEF >40%. The purpose of our work was to evaluate the effectiveness and safety of pathogenetic correction of HF and LVEF>40% with AF in improving treatment outcomes.

Key words: Hypoglycemic agent, empagliflozin, atrial fibrillation, heart failure.

First page

324

Last page

328

For citation: Amonov M.K. – APPLICATION OF A HYPOGLYCEMIC DRUG IN HEART FAILURE WITH PRESERVED EFCILIAR FRACTION WITH AND WITHOUT AFIBLIAR ARRHYTHMIA //New Day in Medicine 2023 12(62): https://newdaymedicine.com/index.php/2023/12/20/l-642/

LIST OF REFERENCES:

1. Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failurewith preserved, mid-range, and reduced ejection fraction. // JACC Heart Fail.2017;5:565-74.
2. Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS,et al.; ESC-HFA HF Long-Term Registry Investigators. Prognostic impli-cations of atrial fibrillation in heart failure with reduced, mid-range, andpreserved ejection fraction: a report from14 964 patients in the EuropeanSociety of Cardiology Heart Failure Long-Term Registry. // Eur Heart J.2018;39:4277-84.
3. Coats AJS, Heymans S, Farmakis D, Anker SD, Backs J, Bauersachs J, et al.Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. // Eur Heart J. 2022;43:863-7.
4. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, et al.;Beta-Blockers in Heart Failure Collaborative Group. Heart rate and rhythmand the benefit of beta-blockers in patients with heart failure. // J Am Coll Cardiol. 2017;69:2885-96.
5. Filippatos G, Farmakis D. How to use beta-blockers in heart failure withreduced ejection fraction and atrial fibrillation. // J Am Coll Cardiol. 2017;69:2897-900.
6. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.;EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a pre-served ejection fraction. // NEngl JMed. 2021;385:1451-61.
7. Böhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, et al.Efficacy of empagliflozin on heart failure and renal outcomes in patients withatrial fibrillation: data from the EMPA-REG OUTCOME trial. // Eur J Heart Fail. 2020;22:126-35.
8. Son MK, Park JJ, Lim NK, Kim WH, Choi DJ. Impact of atrial fibrillation in patientswith heart failure and reduced, mid-range or preserved ejection fraction. // Heart.2020;106:1160-8.
9. Packer M, Lam CSP, Lund LH, Redfield MM. Interdependence of atrial fibrillationand heart failure with a preserved ejection fraction reflects a common underlyingatrial and ventricular myopathy. // Circulation. 2020;141:4-6.
10. Lam CSP, Rienstra M, Tay WT, Liu LCY, Hummel YM, van der Meer P, deBoer RA, Van Gelder IC, van Veldhuisen DJ, Voors AA, Hoendermis ES. Atrialfibrillation in heart failure with preserved ejection fraction: association withexercise capacity, left ventricular filling pressures, natriuretic peptides, and leftatrial volume. // JACC Heart Fail. 2017;5:92-8.
11. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationshipand prognostic significance of atrial fibrillation in heart failure patients withpreserved ejection fraction: a community-based study. // Circulation. 2013;128:1085-93.
12. Wu Y, Xie Z, Liang W, Xue R, Wu Z, Wu D, et al. Usefulness of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for predicting incident atrial fibrilla-tion in heart failure with preserved ejection fraction patients. // ESC Heart Fail. 2021;8:1369-77.
13. Butt  JH,  Docherty  KF,  Jhund  PS,  de  Boer  RA,  Böhm  M,  Desai  AS,et  al.  Dapagliflozin  and  atrial  fibrillation  in  heart  failure with  reducedejection  fraction:  insights  from  DAPA-HF. // Eur  J  Heart  Fail.  2022;24:513-25.
14. Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videbæk L, et al. Associationsof empagliflozin with left ventricular volumes, mass, and function in patientswith heart failure and reduced ejection fraction: a substudy of the Empire HFrandomized clinical trial. // JAMA Cardiol. 2021;6:836-40.
15. Ersbøll M, Jürgens M, Hasbak P, Kjær A, Wolsk E, Zerahn B, et al. Effectof empagliflozin on myocardial structure and function in patients with type 2diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. // Int J Cardiovasc Imaging. 2022;38:579-87.
16. Lan NSR, Yeap BB, Fegan PG, Green G, Rankin JM, Dwivedi G. Empagliflozinand left ventricular diastolic function following an acute coronary syn-drome in patients with type 2 diabetes. // Int J Cardiovasc Imaging. 2021;37:517-27.
17. Li HL, Lip GYH, Feng Q, Fei Y, Tse YK, Wu MZ, et al. Sodium-glucosecotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic reviewand meta-analysis. // Cardiovasc Diabetol. 2021;20:100.
18. Amonov Muhammad Komil o’g’li Orientation to Acute Kidney Injury in Covid-19 // Journal of advanced research and stability (JARS), 2021;1(5).
19. Амонов М.К. (2021). Острое Повреждение Почек При Коронавирусной Болезни (Обзорная Статья). // Central Asian Journal of Medical and Natural Science, 2021;378-382. https://doi.org/10.47494/cajmns.vi0.447
20. Amonov Muhammad Komil Ogli. “Risk factors for severe and critical patients with COVID-19” // Oriental renaissance: Innovative, educational, natural and social sciences, 2021;1(10):1080-1084.